Here, we sought to evaluate difference in PD-L1 expression between tumor cells and stromal immune cells and assess differential prognostic impacts of PD-L1 expression in tumor cells versus stromal immune cells in breast cancer patients. The gene discussed is CD274; the disease is breast carcinoma.